US › Healthcare

X4 Pharmaceuticals Inc (XFOR)

US · Healthcare · Biotechnology

$3.18+3.58%

Last close · 2026-11-06

Latest quarter · ended 2026-09-30

Revenue

$2.9M

Revenue YoY

+63.1%

Net profit

$-20.2M

EPS

$-0.16

EPS estimate

$-0.19

Net margin

-701.6%

EPS came in at -0.16 against a street estimate of -0.19 — a beat of 15.8%.

Key statistics

Market cap

$321.2M

P/E

162.0

Forward P/E

0.0

P/B

2.13

Book value

$1.62

EPS (TTM)

$0.02

52-week high

$4.83

52-week low

$2.43

50-day MA

$3.30

200-day MA

$3.80

Beta

0.47

Analyst view

Analysts rate X4 Pharmaceuticals Inc a strong buy (5 buy, 0 hold, 0 sell out of 5) with an average price target of $11.60.

Shareholding

Insiders

0.45%

Institutions

103.85%

Largest institutional holders

Fund	Stake
Morgan Stanley - Brokerage Accounts	9.54%
FMR Inc	8.39%
Bain Capital Life Sciences Investors, LLC	8.04%
Perceptive Advisors LLC	8.00%
Kalehua Capital Management LLC	7.51%
Saturn V Capital Management LLC	7.03%
Empery Asset Management, LP	6.99%
Deep Track Capital, LP	5.93%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for X4 Pharmaceuticals Inc — free to start.

Open in the app Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc Merck & Company Inc UnitedHealth Group Incorporated Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Gilead Sciences Inc Abbott Laboratories Novo Nordisk A/S

Data updated 2026-11-07.